Who Is Anthony Holland?
Anthony Holland is a music professor at Skidmore College whose research explores frequency-specific oscillation — using precise mechanical/ultrasound frequencies tuned to the resonant frequency of specific cell types. His published work focuses on cancer cells: disrupting their membranes at a frequency that leaves healthy cells largely unaffected — though as I explain further down, none of it has actually gone through peer review yet.
Watch his full talk directly:
The Underlying Idea: Resonance Can Be Selective
Every cell has physical properties — membrane structure, size, internal architecture — that give it a natural resonant frequency. The core claim in this field of research is that a signal tuned closely enough to a specific cell type's resonant frequency can disrupt that cell type while leaving others, with different physical properties, largely unaffected.
The 11th Harmonic — How He Found It
Holland didn't start with one guessed frequency. He tested multiples of a base wave frequency — like harmonics in music, where a string vibrates not just at its base pitch but at whole-number multiples of it. He worked up through these harmonics one at a time.
THE SWING ANALOGY
Think of pushing a kid on a swing. Push at some random moment, and mostly nothing happens — your pushes fight each other. But push at exactly the right moment, in exactly the right rhythm, matching the swing's own natural rhythm, and each small push adds to the last. The swing goes higher and higher, from tiny pushes.
That's resonance. Every object has its own natural rhythm — its own "swing timing." Holland wasn't guessing a random number. He was searching for the exact rhythm that matches a cancer cell's own natural vibration, the same way you'd search for the exact moment to push a swing. Find that rhythm, and small energy builds into a big effect. Miss it, and nothing much happens — which is also part of why the idea is that healthy cells, with a different "rhythm," would be less affected.
At the 11th harmonic, the effect appeared: the target cells visibly broke apart. In a later, more formal 2023 study using a specific frequency range (156–162 kHz, which his team called a "Destructive Cancer Resonant Frequency Formant"), the results were quantified: a 24–43% reduction in leukemia cell growth (38% on average at 160 kHz). That study is a preprint, not yet peer-reviewed. An earlier 2012 study — also not peer-reviewed — found comparable disruption in pancreatic and ovarian cancer cells alongside leukemia.
EVEN TED FLAGGED THIS
TED itself added a note to Holland's talk saying not to treat it as medical advice. That's not a knock against the research — it's exactly the same caution we're applying throughout this course. Real, promising lab research is not the same as a proven treatment.
This isn't unique to Holland's work. A well-known, FDA-approved example in the same broad category: Tumor Treating Fields (Novocure's Optune device), approved for glioblastoma since 2011 and for pancreatic cancer more recently. It uses low-intensity alternating electric fields to disrupt the proteins that anchor a cancer cell's machinery during division — not identical to Holland's mechanism, but the same underlying principle: targeted energy can interfere with cancer cells more than healthy ones. That's real, validated medicine, not fringe theory. Holland's own team is careful not to overstate the connection, though — they say the exact frequency link between their technology and TTFields is "not yet confirmed."
Why This Kind of Research Barely Gets Funded
Quick explainer, in my own words — 80 seconds:
If a specific frequency really can break cancer cells apart, a fair question is: why isn't this already standard treatment everywhere? Not because it's nonsense — but for a reason that has nothing to do with the science: money.
Testing a new drug molecule until it's proven costs close to a billion euros on average, once every failed attempt along the way is counted. Companies accept that cost because they get a patent on the molecule — twenty years where nobody else is allowed to copy it. If the drug works, they earn that investment back.
A frequency is not a molecule. You can patent one specific device with a specific circuit, but you can't own the underlying idea that "this frequency affects this cell type." That means if a company spends ten million euros proving that a given frequency breaks apart cancer cells, a competitor can copy the same signal the following week — without ever paying for the proof.
NOT SUPPRESSED — JUST UNPROFITABLE TO PROVE
Easy to copy, hard to protect. That's the whole reason almost no company is willing to fund the kind of large trial that would settle this properly. It's why Holland has to do this work in a small, underfunded lab instead of with a pharmaceutical-scale budget — not because it isn't interesting, but because nobody gets paid to find out. It's exactly why we're trying to get this tested honestly ourselves, instead of waiting for a drug company to pick it up.
Where My Own Experiment Diverges
Holland's research is about cancer cells, not Helicobacter pylori. I want to be precise here: his work did not study H. pylori. What I did was take the underlying principle — that specific frequencies can affect specific biological targets — and apply it myself, as personal experimentation, to a completely different problem.
That's an important distinction. His research is credible science on its own topic. My application of the idea to H. pylori is something else entirely: an untested personal hypothesis, inspired by his work but not validated by it.
WHY THIS MATTERS
Good research doesn't get diluted by being stretched to cover things it never tested. We're telling you exactly where the solid ground ends and where our own open question begins — that boundary is the whole point of the next step: real lab testing.
References & Resources
Holland, A. (2013). Shattering Cancer with Resonant Frequencies (TEDx). — His original public talk; TED itself added a note that it isn't medical advice.
Holland, A. et al. (2012). Morphological Transformations of Human Cancer Cells and Microtubules Caused by Frequency Specific Pulsed Electric Fields. — Proceedings, 7th International Workshop on Biological Effects of EMF, Malta; leukemia, pancreatic, and ovarian cancer cells. Not a peer-reviewed journal article.
Holland, A. & Bare, J. (2023). Destructive Cancer Resonant Frequency Formant (DCRFF) Reduces Acute Lymphoblastic Leukemia Growth. — Preprint (Preprints.org), not peer-reviewed; a 24–43% reduction in leukemia cell growth at 156–162 kHz.